CME

Host: Anne O'Donnell, MD

Guest: Patrick Flume, MD

Please note: This activity is no longer available for continuing education credit.

Nontuberculous mycobacteria lung disease (NTM-LD) is a relatively uncommon condition, although its prevalence is rising. In this interactive CME activity, Drs. Anne O’Donnell and Patrick Flume review two patient cases to demonstrate how clinicians can maintain a greater index of suspicion for the diagnosis of NTM-LD to enable timely and effective therapy. The management of NTM-LD remains challenging, owing to the need for long-term treatment, the potential for drug-related toxicities and patient nonadherence. These factors underscore the importance of specialty referral for the successful management of NTM-LD.

Host: Anne O'Donnell, MD

Guest: Robert "Brinkley" Sewell

Please note: This activity is no longer available for continuing education credit.

The successful management of nontuberculous mycobacteria lung disease (NTM-LD) remains challenging owing to the need for long-term treatment, the ongoing risks of adverse drug reactions, and the potential for nonadherence. These factors underscore the importance of specialty referral and shared decision making in the successful management of NTM-LD, as Dr. Anne O’Donnell and her patient Brinkley exemplify.

Host: Joseph K. Han, MD

Please note: This activity is no longer available for continuing education credit.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.

Host: Peter A. Lio, MD

Guest: Eric Simpson, MD, MCR

Guest: Mark Boguniewicz, MD

Please note: This activity is no longer available for continuing education credit.

“I begged my doctor for something else – there had to be something else,” Pam.

For over 50 years, Pam suffered with uncontrolled moderate-to-severe atopic dermatitis (AD). She experienced the evolution of treatment strategies over the course of the several decades, trying everything from topicals to off-label targeted systemic agents. She was willing to try anything to make the unbearable itch go away. In this roundtable discussion, we brought Pam and her dermatologist to discuss AD with a multidisciplinary physician panel. Together they weigh in on experimental and newly approved therapies, management strategies, impact on quality-of-life, and shared decision-making techniques, all supplemented by Pam’s unfiltered, down-to-earth reality check of what life with AD and all these drugs really feels like.

Host: Shira Johnson, MD

Guest: Amy L. Olson, MD, MSPH

Guest: Jeffrey Swigris, DO, MS

Guest: Katherine Rosen, RN, MSN, ANP-C

Please note: This activity is no longer available for continuing education credit.

This discussion highlights the challenges associated with progressive-fibrosing ILD diagnosis, explains management differences for connective tissue disease-associated ILD, and reviews therapeutic options for the management of PF-ILD.

Host: Shira Johnson, MD

Guest: Amy L. Olson, MD, MSPH

Guest: Jeffrey Swigris, DO, MS

Guest: Katherine Rosen, RN, MSN, ANP-C

Please note: This activity is no longer available for continuing education credit.

This discussion highlights the diagnosis of and treatment approach for interstitial pneumonia with autoimmune features (IPAF).

Host: Eric H. Kraut, MD

Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.

Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when …

Host: Leora Horn, MD, MSc

Please note: This activity is no longer available for continuing education credit.

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

Host: Patricia K. Coyle, MD

Guest: Clyde E. Markowitz, MD

Please note: This activity is no longer available for continuing education credit.

Multiple sclerosis (MS) is one of the leading causes of disability worldwide. As the treatment armamentarium continues to grow, patient involvement in the development of an effective treatment strategy is becoming increasingly important. In this Clinical ExchangesSM activity, leading MS specialists discuss issues of diagnosing MS, initiating treatment, and switching therapies, all in the context of practical shared decision-making techniques demonstrated by their own patients.

Guest: Robert A. Baldor, MD

Guest: Chadwick R. Johr, MD

This innovative, 45-minute, case-based CME activity features two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. In addition to the analysis of AI cases, key topics will be covered, including:

• Evaluation for suspected RA
• Combination serological assessment
• 14-3-3eta as a marker for joint damage
• Autoantibodies in SLE diagnosis and classification
• ANA IFA and subserologies
• Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis